当前位置: 首页 > 期刊 > 《新医学》 > 20181
编号:13604948
肝硬化合并门静脉血栓的抗凝治疗进展(6)
http://www.100md.com 2018年1月1日 《新医学》 20181
     [26]Arnao V, Riolo M, Tuttolomondo A, Pinto A, Fierro B, Aridon P New frontiers in anticoagulation: non vitaminK oral anticoagulants in stroke prevention Expert Rev Neurother, 2017,17(6):539552

    [27]Intagliata NM, Maitland H, Caldwell SH Direct oral anticoagulants in cirrhosis Curr Treat Options Gastroenterol, 2016,14(2):247256

    [28]Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation Dig Dis Sci, 2016,61(6):17211727

    [29]Pollack CJ Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI Idarucizumab for dabigatran reversal N Engl J Med, 2015,373(6):511520

    [30]Nafee T, Aslam A, Chi G, Pahlavani S, Nimri D, Kuchkuntla AR, Talib U, Michalak N, Daaboul Y, Korjian S, Gallo A, Gibson CM Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors Expert Rev Cardiovasc Ther, 2017,15(4):237245

    [31]Cho E, Jun CH, Cho SB, Park CH, Kim HS, Choi SK, Rew JS Endoscopic variceal ligationinduced ulcer bleeding: what are the risk factors and treatment strategies? Medicine (Baltimore), 2017,96(24):e7157

    (收稿日期:20170906), 百拇医药(杨智炜 吴斌)
上一页1 2 3 4 5 6